-
公开(公告)号：US20240335517A1
公开(公告)日：2024-10-10
申请号：US18493262
申请日：2023-10-24
IPC分类号： A61K38/52 , A23L29/00 , A23L33/10 , A23L33/18 , A23L33/20 , A61K9/48 , A61K38/44 , A61K38/54 , A61P1/00
CPC分类号： A61K38/52 , A23L29/06 , A23L33/10 , A23L33/18 , A23L33/20 , A61K9/485 , A61K9/4858 , A61K38/44 , A61K38/54 , A61P1/00 , C12Y101/99011 , C12Y302/0102 , C12Y302/01026 , C12Y503/01005 , A23V2002/00 , A61K2300/00
摘要： There is provided a method for treating or reducing the effects of fructose intolerance and health problems associated with excessive fructose intake by administration of glucose isomerase. Other embodiments are also disclosed.
-
公开(公告)号：US20240245761A1
公开(公告)日：2024-07-25
申请号：US18583069
申请日：2024-02-21
申请人： Curemark, LLC
CPC分类号： A61K38/54 , A61K38/465 , A61K38/47 , A61K38/48
摘要： Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of Celiac disease. Also described herein is a method for treating a subject with Celiac disease using digestive enzymes and their derivatives to alleviate the symptoms of Celiac disease. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of Celiac disease.
-
公开(公告)号：US11950569B2
公开(公告)日：2024-04-09
申请号：US16611658
申请日：2018-05-08
申请人： Novozymes A/S
CPC分类号： A01K15/026 , A23K50/40 , A61K38/54
摘要： The invention provides an animal chew toy comprising a dental care composition, wherein the dental care composition comprises at least one peroxidase and at least one oxidase.
-
公开(公告)号：US20230127775A1
公开(公告)日：2023-04-27
申请号：US17930014
申请日：2022-09-06
IPC分类号： A61K38/48 , A61K38/05 , A61K38/54 , A61K31/198 , A61K31/454 , A61K31/475 , A61K31/573 , A61K31/675 , A61K31/69 , A61K31/704 , A61K35/12 , A61P25/28 , A61K45/06 , C12N9/48 , C12N9/64
摘要： Methods and compositions for the treatment or prevention of amyloidosis are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of at least one catabolic enzyme or a biologically active fragment thereof. Such methods and compositions may be employed to reduce, prevent, degrade and/or eliminate amyloid formation in the lysosome and/or extracellularly.
-
公开(公告)号：US20220339269A1
公开(公告)日：2022-10-27
申请号：US17640918
申请日：2020-09-03
摘要： The invention relates to a pharmaceutical composition of the cores of microgranules containing pancreatin, cetyl alcohol, poloxamer 407 in predetermined quantities, the production method, as well as the production of the water-based enteric-coated microgranules. Furthermore, the resulting oral dosage form does not contain residual acetone. The technical result is in achieving higher stability of the cores and the enteric-coated microgranules, respectively, while maintaining the good solubility of the enteric-coated microgranules, which allows the application of the claimed pancreatin microgranules for the preparation of safe and non-toxic drugs for the treatment of digestive disorders.
-
公开(公告)号：US11458221B2
公开(公告)日：2022-10-04
申请号：US16540291
申请日：2019-08-14
发明人： Hyunjoon Kong , Yongbeom Seo , Jiayu Leong , Yu-Heng Deng
摘要： Diatom microbubblers comprising diatom biosilica or other silica linked to a catalyst for the decomposition of hydrogen peroxide, such as manganese oxide (MnO2), platinum (Pt), CuO (copper II oxide), or zinc peroxide (ZnO2) particles or nanosheets, or catalase are provided. Further provided are methods of reducing or eliminating biofilm or biofouling conditions.
-
公开(公告)号：US11160850B2
公开(公告)日：2021-11-02
申请号：US16231195
申请日：2018-12-21
申请人： Baxalta Incorporated , Baxalta GmbH
摘要： Disclosed herein are compositions and methods for improving hemostasis in the treatment of bleeding disorders and reversal of anticoagulant activity. Effective ratios of prothrombin (FII) and activated factor X (FXa) for the treatment of bleeding disorders that are as efficacious as FEIBA®, but require a lower concentration of FII are described herein.
-
公开(公告)号：US11110154B2
公开(公告)日：2021-09-07
申请号：US14706747
申请日：2015-05-07
IPC分类号： A61K38/00 , A61K39/00 , A61K48/00 , A61P25/00 , A61P25/14 , A61P25/28 , C07K19/00 , C12N15/62 , C12N15/86 , A61K38/54 , A61K38/46 , A61K38/18 , A61K38/17 , C12N15/864 , C12N15/63
摘要： Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.
-
公开(公告)号：US20210228694A1
公开(公告)日：2021-07-29
申请号：US17065836
申请日：2020-10-08
IPC分类号： A61K38/48 , A61K38/05 , A61K38/54 , A61K31/198 , A61K31/454 , A61K31/475 , A61K31/573 , A61K31/675 , A61K31/69 , A61K31/704 , A61K35/12 , A61P25/28 , A61K45/06 , C12N9/48 , C12N9/64
摘要： Methods and compositions for the treatment or prevention of amyloidosis are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of at least one catabolic enzyme or a biologically active fragment thereof. Such methods and compositions may be employed to reduce, prevent, degrade and/or eliminate amyloid formation in the lysosome and/or extracellularly.
-
公开(公告)号：US20210162024A1
公开(公告)日：2021-06-03
申请号：US16983352
申请日：2020-08-03
申请人： Curemark, LLC
IPC分类号： A61K38/48 , A61K31/122 , A61K38/46 , A61K38/47 , A61K38/54
摘要： Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having behavioral disorders, neurological disorders or mental health disorders. Disclosed herein are methods of treating core and non-core symptoms of behavioral disorders, neurological disorders or mental health disorders. Also disclosed herein are products for use in methods of treatment and methods of making the same.
-
-
-
-
-
-
-
-
-
搜索结果
887 条记录 (耗时 0.028 秒)
